Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure | Zendy

Davide Castagno | Zendy; Mark C. Petrie | Zendy; Brian Claggett | Zendy; John J.V. McMurray | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure

Author(s) -

Davide Castagno,

Mark C. Petrie,

Brian Claggett,

John J.V. McMurray

Publication year - 2012

Publication title -

european heart journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.336

H-Index - 293

eISSN - 1522-9645

pISSN - 0195-668X

DOI - 10.1093/eurheartj/ehs004

Subject(s) - ivabradine , digoxin , medicine , heart failure , cardiology , heart rate , digitalis , ejection fraction , clinical endpoint , clinical trial , blood pressure

The importance of heart rate in the pathophysiology of heart failure with reduced LVEF has recently attracted attention. In particular, the findings of the Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial (SHIFT) have put special emphasis on heart rate reduction with ivabradine for improvement in clinical outcomes. Of course, there is a much older drug that reduces heart rate, i.e. digoxin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research